- Home
- AREB vs TCRT Comparison
AREB vs TCRT Comparison
Compare AREB & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AREB
- TCRT
- Stock Information
- Founded
- AREB 2014
- TCRT 1998
- Country
- AREB United States
- TCRT United States
- Employees
- AREB N/A
- TCRT N/A
- Industry
- AREB Plastic Products
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- AREB Industrials
- TCRT Health Care
- Exchange
- AREB Nasdaq
- TCRT Nasdaq
- Market Cap
- AREB 2.8M
- TCRT 2.5M
- IPO Year
- AREB N/A
- TCRT N/A
- Fundamental
- Price
- AREB $6.29
- TCRT $2.80
- Analyst Decision
- AREB
- TCRT
- Analyst Count
- AREB 0
- TCRT 0
- Target Price
- AREB N/A
- TCRT N/A
- AVG Volume (30 Days)
- AREB 4.3M
- TCRT 946.1K
- Earning Date
- AREB 04-11-2025
- TCRT 05-14-2025
- Dividend Yield
- AREB N/A
- TCRT N/A
- EPS Growth
- AREB N/A
- TCRT N/A
- EPS
- AREB N/A
- TCRT N/A
- Revenue
- AREB $14,447,104.00
- TCRT $10,000.00
- Revenue This Year
- AREB $45.19
- TCRT $5,680,500.00
- Revenue Next Year
- AREB N/A
- TCRT N/A
- P/E Ratio
- AREB N/A
- TCRT N/A
- Revenue Growth
- AREB N/A
- TCRT 100.00
- 52 Week Low
- AREB $1.10
- TCRT $1.31
- 52 Week High
- AREB $231.75
- TCRT $18.50
- Technical
- Relative Strength Index (RSI)
- AREB 41.52
- TCRT 83.32
- Support Level
- AREB $1.10
- TCRT $1.31
- Resistance Level
- AREB $4.00
- TCRT $1.60
- Average True Range (ATR)
- AREB 1.46
- TCRT 0.24
- MACD
- AREB 0.95
- TCRT 0.11
- Stochastic Oscillator
- AREB 70.61
- TCRT 78.22
About AREB American Rebel Holdings Inc.
American Rebel Holdings Inc develops self-defense, safe storage, and patriotic products. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, vault doors, and Others.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.